MPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI) today reported financial results for the second quarter of 2011. The net loss for the quarter ended June 30, 2011 was $10.7 million compared with a net loss of $12.9 million for the quarter ended June 30, 2010. “The Phase IIb Capesaris Maintenance Dose clinical trial for first line hormonal therapy in men with advanced prostate cancer is enrolling as planned,” said Mitchell S. Steiner, MD, CEO of GTx. “We also expect to initiate this year both a Phase II Capesaris Loading Dose clinical trial for first line hormonal therapy in men with advanced prostate cancer and a Phase II Capesaris clinical trial for second line hormonal therapy in men on androgen deprivation therapy with castration resistant prostate cancer.”
